Spots Global Cancer Trial Database for epirubicin
Every month we try and update this database with for epirubicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial | NCT04872985 | Breast Cancer Hormone-recepto... | Pyrotinib Epirubicin Doxorubicin Hyd... Cyclophosphamid... Docetaxel Nab paclitaxel Placebo | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Phase II Trial for Large ER-Negative Breast Cancers | NCT01869192 | Malignant Neopl... | Epirubicin Cyclophosphamid... Docetaxel Capecitabine Radiation Thera... | 18 Years - | University of Colorado, Denver | |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | NCT01855828 | Her2-Positive B... | Pertuzumab Trastuzumab Paclitaxel 5-fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 65 Years | Yale University | |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | NCT00431080 | Breast Cancer | Docetaxel Paclitaxel Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | NCT00957125 | Breast Cancer | Epirubicin Docetaxel Bevacizumab | 18 Years - | Karolinska University Hospital | |
| Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer | NCT03647280 | Breast Cancer | Abraxane Epirubicin | 18 Years - 60 Years | Zhejiang Cancer Hospital | |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer | NCT00123318 | Gastric Cancer | epirubicin cisplatin 5-fluorouracil Radiotherapy | 18 Years - | Trans Tasman Radiation Oncology Group | |
| ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | NCT03286634 | Down Syndrome Acute Lymphobla... Childhood Cance... | Daunorubicin Prednisolone Vincristine Epirubicin E-coli L-aspara... 6-Mercaptopurin... Methotrexate Hydrocortisone Cytarabine Cyclophosphamid... | 0 Years - 20 Years | National Hospital Organization Nagoya Medical Center | |
| Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer | NCT04224922 | Breast Cancer | Paclitaxel Carboplatinum Epirubicin Cyclophosphamid... | 18 Years - | AZ-VUB | |
| Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) | NCT04127019 | Primary Breast ... | Paclitaxel Docetaxel Cyclophosphamid... Epirubicin 5-fluorouracil | 18 Years - 75 Years | Fudan University | |
| A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. | NCT00454636 | Gastric Cancer | Cisplatin Capecitabine Epirubicin Cisplatin Capecitabine Oxaliplatin Docetaxel Capecitabine | 18 Years - | Hoffmann-La Roche | |
| Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | NCT05287308 | Breast Cancer | doxorubicin epirubicin pirarubicin cyclophosphamid... albumin-bound p... paclitaxel docetaxel | 18 Years - 70 Years | ChineseAMS | |
| Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) | NCT04031703 | Breast Cancer | Paclitaxel Carboplatin Epirubicin Cyclophosphamid... 5-fluorouracil Docetaxel | 18 Years - 65 Years | Fudan University | |
| BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer | NCT00540800 | Breast Cancer | docetaxel epirubicin capecitabine | - 70 Years | National Cancer Institute, Naples | |
| Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer | NCT00615602 | Breast Cancer | Docetaxel Trastuzumab Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... Trastuzumab | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) | NCT01690325 | Breast Cancer | Docetaxel Trastuzumab Bevacizumab Epirubicin Cyclophosphamid | 18 Years - 65 Years | West German Study Group | |
| Adjuvant FEC Versus EP in Breast Cancer (MIG5) | NCT02450058 | Breast Cancer Chemotherapy, A... | 5-fluorouracil epirubicin cyclophosphamid... epirubicin paclitaxel | 18 Years - 70 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer | NCT01061359 | Breast Neoplasm | Epirubicin: Obs... | - | Pfizer | |
| The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | NCT02395640 | Gastric Cancer | Epirubicin Oxaliplatin Capecitabine | 18 Years - 70 Years | Fudan University | |
| Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer | NCT02685059 | Breast Cancer | MEDI4736 (Anti ... Placebo nab-Paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | German Breast Group | |
| A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | NCT01966471 | Breast Cancer | Trastuzumab Emt... Trastuzumab Pertuzumab Paclitaxel Epirubicin Doxorubicin Docetaxel Cyclophosphamid... 5-Fluorouracil | 18 Years - | Hoffmann-La Roche | |
| ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer | NCT01779206 | Breast Cancer | Epirubicin Cyclophosphamid... Docetaxel Paclitaxel | 18 Years - | West German Study Group | |
| Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) | NCT04947059 | Bladder Cancer | Gemcitabine Hyd... Epirubicin Hydr... | 18 Years - 100 Years | University of Thessaly | |
| Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | NCT00215644 | Esophageal Canc... Gastric Cancer | Matuzumab Epirubicin Cisplatin Capecitabine | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Study for the Neoadjuvant Treatment of Breast Cancer | NCT05420454 | Breast Cancer | Docetaxel Carboplatin Trastuzumab Pertuzumab Nab paclitaxel Epirubicin Cyclophosphamid... Docetaxel Epirubicin Cyclophosphamid... Nab paclitaxel | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma | NCT05053386 | Hepatocellular ... | Idarubicin Hydr... Epirubicin | 18 Years - 80 Years | Zhejiang Cancer Hospital | |
| Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer | NCT00193050 | Breast Cancer | Gemcitabine Epirubicin Docetaxel | 18 Years - | SCRI Development Innovations, LLC | |
| Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer | NCT01479036 | Breast Cancer | docetaxel and e... docetaxel and e... | 18 Years - 70 Years | Xijing Hospital | |
| Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | NCT01204801 | Breast Cancer | Focused Microwa... Chemotherapy (c... | 18 Years - | Medifocus, Inc. | |
| Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy | NCT03349177 | Breast Cancer Pathological Co... Neoadjuvant Che... | Epirubicin Fluorouracil Docetaxel Cyclophosphamid... | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | NCT04676997 | Triple Negative... | Camrelizumab Nab paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | NCT02627248 | Breast Cancer | Huaier Granule Epirubicin Docetaxel Cyclophosphamid... | 18 Years - | Shandong University | |
| A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer | NCT01710592 | Gastro Oesophag... | Epirubicin Oxaliplatin Capecitabine Docetaxel | 18 Years - | Cancer Trials Ireland | |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | NCT00431080 | Breast Cancer | Docetaxel Paclitaxel Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation | NCT02631499 | Carcinoma, Hepa... Neoplastic Cell... | TACE Epirubicin lipiodol | 18 Years - 75 Years | Fudan University | |
| BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | NCT00625898 | Breast Cancer | Docetaxel Trastuzumab Carboplatin Bevacizumab 5-Fluorouracil Epirubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma | NCT04214626 | Diffuse Large B... | Rituximab Lenalidomide Cyclophosphamid... Epirubicin Vincristine Prednisone Methotrexate | 18 Years - 70 Years | Henan Cancer Hospital | |
| Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | NCT05447702 | Triple Negative... | Camrelizumab Apatinib Nab-paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 75 Years | West China Hospital | |
| 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer | NCT01216644 | Gastric Cancer | 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel Epirubicin Cisplatin 5-fluorouracil | 18 Years - | Krankenhaus Nordwest | |
| The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | NCT02395640 | Gastric Cancer | Epirubicin Oxaliplatin Capecitabine | 18 Years - 70 Years | Fudan University | |
| Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients | NCT00270894 | Breast Neoplasm | epirubicin cyclophosphamid... docetaxel trastuzumab | 18 Years - | Accelerated Community Oncology Research Network | |
| Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer | NCT02949258 | Stomach Neoplas... Gastric Cancer | oxaliplatin etoposide epirubicin S1 | 30 Years - 75 Years | Jinling Hospital, China | |
| Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | NCT04899570 | Intravascular L... | Zanubrutinib Rituximab Cyclophosphamid... Epirubicin Vindesine Prednisone | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | NCT00556127 | Diffuse Large B... POOR PROGNOSIS | Rituximab Epirubicin Cyclophosphamid... Vincristine Prednisone Granulocyte-col... Mitoxantrone Cytarabine ARA-... Dexamethasone Carmustine BCNU Etoposide Melphalan Radiotherapy PBSC reinfusion | 18 Years - 60 Years | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | |
| Precise Neoadjuvant Chemoresection of Low Grade NMIBC | NCT06227065 | Bladder Cancer Non-muscle Inva... Low-risk | Epirubicin Mitomycin Gemcitabine Docetaxel | 18 Years - | University of Bern | |
| Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | NCT00176488 | Breast Cancer | epirubicin vinorelbine | 21 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | NCT06121570 | Breast Neoplasm... | Sentinel Lymph ... Doxorubicin Epirubicin Cyclophosphamid... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Nab-paclitaxel | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | NCT00309569 | Early Stage Bre... | Cyclophosphamid... Methotrexate Fluorouracil Epirubicin Surgery | 18 Years - 80 Years | Austrian Breast & Colorectal Cancer Study Group | |
| Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates | NCT00130936 | Gastric Cancer Esophageal Canc... Tumors | Epirubicin Carboplatin Capecitabine | 18 Years - 70 Years | AHS Cancer Control Alberta | |
| A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. | NCT00454636 | Gastric Cancer | Cisplatin Capecitabine Epirubicin Cisplatin Capecitabine Oxaliplatin Docetaxel Capecitabine | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | NCT03289819 | Malignant Neopl... | Pembrolizumab nab-paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | Institut fuer Frauengesundheit | |
| A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | NCT05681728 | Breast Cancer | Pembrolizumab Paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Reduced Chemotherapy in Low Risk DLBCL | NCT02752815 | Diffuse Large B... | Rituximab Cyclophosphamid... Epirubicin Vincristine Prednisone | 14 Years - 75 Years | Ruijin Hospital | |
| Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer | NCT04136782 | Breast Cancer | Albumin-bound p... Epirubicin comb... | 18 Years - 70 Years | Shengjing Hospital | |
| Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC) | NCT00154739 | Non-Small Cell ... | Gemcitabine Cisplatin Epirubicin | 18 Years - | National Taiwan University Hospital | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | NCT00336791 | Breast Cancer | 5-Fluorouracil Cyclophosphamid... Doxorubicin Paclitaxel Epirubicin | - | M.D. Anderson Cancer Center | |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | NCT01855828 | Her2-Positive B... | Pertuzumab Trastuzumab Paclitaxel 5-fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 65 Years | Yale University | |
| A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | NCT01358877 | Breast Cancer | 5-Fluorouracil Carboplatin Cyclophosphamid... Docetaxel Doxorubicin Epirubicin Paclitaxel Pertuzumab Placebo Trastuzumab | 18 Years - | Hoffmann-La Roche | |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | NCT02125344 | Tubular Breast ... Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... HER2 Positive B... Inflammatory Br... | non-pegylated l... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Pertuzumab Trastuzumab Ferric carboxym... | 18 Years - | German Breast Group | |
| Phase I Combination w/ Epirubicin | NCT00322374 | Metastatic Brea... | Ixabepilone Epirubicin | 18 Years - | R-Pharm | |
| Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer | NCT01830270 | Stomach Neoplas... Oesophageal Jun... Lower Oesophagu... | Epirubicin Cisplatin Paclitaxel gastric surgery | 18 Years - 70 Years | Centre Hospitalier Universitaire de Besancon | |
| Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies | NCT00246103 | Neoplasms, Adva... | Valproic acid Epirubicin 5-fluorouracil Cyclophosphamid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer | NCT02897050 | Breast Cancer | Docetaxel Capecitabine Cyclophosphamid... Fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| TACE With Dicycloplatin(TP21) in Unresectable HCC | NCT05472896 | Hepatocellular ... | cTACE Dicycloplatin (... Epirubicin | 18 Years - | Zhongda Hospital | |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | NCT05681728 | Breast Cancer | Pembrolizumab Paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | NCT00054587 | Breast Cancer | Trastuzumab Cyclophosphamid... docetaxel Epirubicin Fluorouracil | 18 Years - 64 Years | UNICANCER | |
| Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | NCT00450203 | Oesophagogastri... | bevacizumab capecitabine cisplatin Epirubicin adjuvant therap... conventional su... neoadjuvant the... Lapatinib | 18 Years - | Medical Research Council | |
| Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | NCT02871869 | Diffuse, Large ... | vindesine cyclophosphamid... Epirubicin prednisone tabl... Cinobufacini Ta... Rituximab | 18 Years - 70 Years | Xinjiang Medical University | |
| Reduced Chemotherapy in Low Risk DLBCL | NCT02752815 | Diffuse Large B... | Rituximab Cyclophosphamid... Epirubicin Vincristine Prednisone | 14 Years - 75 Years | Ruijin Hospital | |
| A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | NCT00957125 | Breast Cancer | Epirubicin Docetaxel Bevacizumab | 18 Years - | Karolinska University Hospital | |
| TCb vs EC-T in High Risk ER+/HER2- Breast Cancer | NCT05901428 | Hormone Recepto... | Docetaxel Carboplatin Epirubicin Cyclophosphamid... | 18 Years - 70 Years | Fudan University | |
| Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | NCT00464646 | Breast Cancer | Epirubicin Cyclophosphamid... Docetaxel Trastuzumab Bevacizumab | 18 Years - | NSABP Foundation Inc | |
| Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | NCT03373708 | Breast Cancer Chemotherapy Endocrine Breas... | Epirubicin Cyclophosphamid... Docetaxel Goserelin aceta... Tamoxifen Letrozole | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients | NCT01740271 | Breast Neoplasm... | Epirubicin | 18 Years - | AHS Cancer Control Alberta | |
| Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | NCT00309569 | Early Stage Bre... | Cyclophosphamid... Methotrexate Fluorouracil Epirubicin Surgery | 18 Years - 80 Years | Austrian Breast & Colorectal Cancer Study Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
